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Synopsis
The plasma level of LPA (lysophosphatidic acid) (200–600 nM) is well within the range that promotes proliferation and
migration of vascular ECs (endothelial cells), yet vessels are quiescent and stable. In this report, we considered one
explanation for this paradox: that ECs secrete agents that attenuate responsiveness to LPA. Indeed, we observed
that CM (conditioned medium) from conﬂuent, quiescent cultures of primary HUVECs (human umbilical vein ECs)
contained an agent that inhibited LPA-mediated signalling events and cellular responses. The putative inhibitor, which
we tentatively call ILMR (inhibitor of LPA-mediated responsiveness) seemed to act on cells (instead of at the level
of LPA) by suppressing the ability of LPA receptor 1 to signal. The amount and/or activity of ILMR was regulated by
growth factors; exposing HUVECs to VEGF-A (vascular endothelial growth factor A), but not bFGF (basic ﬁbroblast growth
factor), reduced the amount and/or activity of ILMR in CM. We conclude that in addition to promoting angiogenesis
directly, VEGF-A can also act indirectly by modulating the bioactivity of angiomodulators such as LPA.
Key words: conditioned medium, endothelial cell, intracellular signalling, lysophosphatidic acid, vascular
endothelial growth factor A.
Cite this article as: Park, E.Y. and Kazlauskas, A. (2012) Primary human endothelial cells secrete agents that reduce
responsiveness to lysophosphatidic acid (LPA). Biosci. Rep. 32, 393–400
INTRODUCTION
LPA(lysophosphatidicacid)stimulatesavarietyofcellularactiv-
ities (cytoskeleton remodelling, ion transport and cell survival)
by engaging one or more of its six GPCRs (G-protein-coupled
receptors) [1–4]. For instance, LPA promotes migration of ECs
(endothelial cells), and mice that lack autotaxin, an enzyme that
produces LPA, display vascular defects and embryonic lethality
[5,6]. Furthermore, LPA promotes regression of unstable vascu-
lar beds [7]. These observations indicate that LPA is one of the
agents that contribute to angiogenic homoeostasis.
ECs lining vessels of healthy individuals are quiescent des-
pite their continual exposure to an activating concentration of
LPA [1]. This phenomenon supports the idea that the quant-
ity/availability of LPA and expression of LPA receptors is only a
subsetofmechanismsthatgovernresponsivenesstoLPA.Indeed,
............................................................................................................................................................................................................................................................................................................
Abbreviations used: bFGF, basic ﬁbroblast growth factor; CM, conditioned medium; DMEM, Dulbecco’s modiﬁed Eagle’s medium; EC, endothelial cell; ERK, extracellular-signal-
regulated kinase; GPCR, G-protein-coupled receptor; HDMVEC, human dermal microvessel EC; HUVEC, human umbilical vein EC; ILMR, inhibitor of LPA-mediated responsiveness; LPA,
lysophosphatidic acid; LPAAT, LPA acyltransferase; LPA1, LPA receptor 1; LPP , lipid phosphate phosphatase; VEGF-A, vascular endothelial growth factor A.
1 To whom correspondence should be addressed (email andrius_kazlauskas@meei.harvard.edu).
circulating proteins such as albumin and gelsolin bind LPA and
regulate its activity [8–10]. Cells express LPPs (lipid phosphate
phosphatases), which are transmembrane enzymes that dephos-
phorylate and thereby inactivate LPA [11]. Furthermore, intra-
cellular signalling can desensitize LPA receptors, and thereby
reduce LPA responsiveness [12,13]. These ﬁndings indicate that
the bioactivity of LPA can be regulated at multiple levels, and
one or more of these mechanisms are likely explanations for how
vascular ECs remain quiescent when exposed to circulating LPA.
In the present study, we developed a cell-based assay to gauge
the bioactivity of LPA and used it to discover that primary hu-
man ECs secreted agents that attenuated the responsiveness of
cells to LPA. This agent appeared to suppress LPA-mediated sig-
nallingoftheLPA1(LPAreceptor1).Finally,theamount/activity
of this agent was reduced by VEGF-A (vascular endothelial
growth factor A), but not bFGF (basic ﬁbroblast growth factor).
We conclude that primary human ECs have the potential to
C   2012 The Author(s) This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/
by-nc/2.5/) which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.
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self-regulate their responsiveness to LPA, and that this phe-
nomenon is under the control of VEGF-A.
EXPERIMENTAL
Cell culture
The rat hepatoma cell line (RH7777) containing an empty vec-
tor (V) or LPA1 (L1) were kindly provided by Dr Xianjun Fang
(Department of Biochemistry, Virginia Commonwealth Univer-
sity, Richmond, VA, U.S.A.) [14]. They were maintained in
DMEM (Dulbecco’s modiﬁed Eagle’s medium) supplemented
with 10% fetal bovine serum, 80 units/ml penicillin and strepto-
mycin C. HUVECs (human umbilical vein ECs) were purchased
from Lonza and plated on gelatin (0.2%)-coated dishes. HDM-
VECs (human dermal microvessel ECs) were kindly provided by
Dr Rong Shao (Department of Veterinary and Animal Science,
UniversityofMassachusetts,Amherst,MA,U.S.A.).AllEClines
were maintained in M199 media supplemented with 20% bovine
calf serum, 80 units/ml penicillin and streptomycin C, 12 μg/ml
bovine brain extract and 100 μg/ml heparin at 37◦Ci n5%C O 2.
Antibodies and reagents
Anti-LPA1 (NBP1-03363) was purchased from Novus Bio-
logy. Anti-gelsolin (sc-6405) and anti-c-Met (sc-10) were
purchased from Santa Cruz Biotechnology. Anti-phospho-
ERK (extracellular-signal-regulated kinase) (#9101) and U0126
(39903) was purchased from Cell Signaling. Gelsolin (G1538)
and cycloheximide were purchased from Sigma. Ki16425 and
SU6656 were purchased from Cayman Chemicals and Calbio-
chem respectively. LPA (L7260; Sigma) was dissolved in PBS
containing 0.5% fatty-acid-free BSA (#3117405001; Roche) to
a ﬁnal stock concentration of 3.5 mM. VEGF-A and bFGF were
kindly provided by NCBI.
LPA bioassay
L1 and V cells were plated at a density of 2×104 cells/well into a
48-well plate coated with polylysine and incubated overnight in
culture media. Cells were subsequently serum starved for 48 h,
duringwhichtimethemediumwaschangedeveryday.Afterstar-
vation, cells were treated with LPA in either serum-free DMEM,
or CM (conditioned medium) for 1 h at 37◦Ci nt h e5%C O 2 in-
cubator.Inpre-treatmentexperiments,cellswerepre-treatedwith
either serum-free DMEM or CM for 1 h, washed with serum-
free DMEM once, and then treated with LPA in DMEM for an
additional 1 h. CM was generated by growing HUVEC to con-
ﬂuence, incubating for 16–18 h in serum-free DMEM with or
without 10 ng/ml VEGF-A or 10 ng/ml bFGF. The resulting CM
was centrifuged and the supernatant was used in experiments as
described below.
To monitor phosphorylation of paxillin, cells were stimulated
as described below, rinsed once with ice-cold PBS and lysed for
Figure 1 LPA induced the phosphorylation of paxillin in a dose-
dependent manner
(A) Rat hepatoma cells Rh7777 stably expressing LPA1 (L1) or empty
vector (V) were harvested and subjected to Western blot analysis using
an anti-LPA1 or an anti-RasGAP antibody. (B) L1 and V cells were ex-
posed for 1 h to the indicated amount of LPA in serum-free DMEM. Cell
lysates were subjected to phospho-paxillin (p-paxillin) Western blot ana-
lysis. The signal intensity was quantiﬁed and normalized to the loading
control (RasGAP). The LPA1-speciﬁc response was calculated by sub-
tracting the normalized phospho-paxillin response in V cells from L1
cells. (C) The LPA1-speciﬁc response was plotted as a function of LPA
concentration. The linear range of this assay was 0–200 nM.
30 min at room temperature (21◦C) with rocking in SDS sample
buffer [2 mM EDTA, 2% SDS, 50 mM Tris/HCl (pH 6.8), 10%
glycerol,5%2-mercaptoethanoland0.01%BromophenolBlue].
Westernblotanalysiswasperformedasdescribedpreviously[15]
with the following minor modiﬁcations. Samples were boiled
for 7 min and resolved by SDS/PAGE (8% gel). Membranes
wereincubatedovernightwitha1:5000dilutionofanti-phospho-
paxillin antibody (#2541; Cell Signaling) and a 1:100000 dilu-
tion of an anti-RasGAP antibody [16] (loading control). The
signal intensity was quantiﬁed using BioRad Quantity One
software.
Radioenzymatic assay
Radioenzymatic assay was performed as described previously
[13,17]. In this assay, LPA was converted into [14C]PA (phos-
phatidic acid) in the presence of recombinant LPAAT (LPA acyl-
transferase) and [14C]oleoyl-CoA. LPAAT was prepared from
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Figure 2 HUVECs secreted agent(s) that suppressed the bioactivity of LPA
(A) The cells described in Figure 1 were either left resting (−), or stimulated for 1 h with 50 nM LPA (+) in the presence
of CM or DMEM (mock CM). Cells were harvested and subjected to Western blot analysis as described in Figure 1. The
lower panel is a histogram of the means+ −S.E.M. from three independent experiments. *P<0.05. CM was generated by
incubating serum-free DMEM with conﬂuent, quiescent HUVECs for 16–18 h. (B) 50 nM LPA was incubated with either
DMEM or CM for 1 h and then the amount of LPA was quantiﬁed using the radioezymatic assay described in the Experimental
section. The top panel is a representative autoradiogram. The normalized intensity was calculated by subtracting the signal
of control samples (−) from the signal of LPA-containing samples (+). The lower panel is a histogram of means+ −S.E.M.
from three independent experiments. n.s.: not signiﬁcant. These data indicate that CM attenuated the response to LPA
without degrading it.
bacteria expressing the rat 1 acyl-sn-glycerol-3-phosphate acyl-
transferase cDNA, which was obtained from Dr Kazuhiko Kume
(Department of Biochemistry and Molecular Biology, Faculty of
Medicine, University of Tokyo, Tokyo, Japan) [18].
Migration assay
Transwells (5 μm pore; #3422; Corning) were pre-wetted with
serum-free DMEM for 2 h prior to use. HDMVECs were plated
at 2×105 per chamber in serum-free DMEM, chemo-attractants
were added to the bottom wells and incubated for either 4 h, or
overnight at 37◦Ci n5 %C O 2 incubator. Migrated cells were
stained with 0.5% Crystal Violet. Crystal Violet was extracted
with 10% acetic acid and the A560 quantiﬁed.
Membrane fractionation
Cells were plated at 106 cells/10 cm dish coated with polylysine,
cultured and starved as described in LPA bioassay section. The
resulting cells were pre-treated either with serum-free DMEM or
CMfor1 h,rinsedoncewithserum-freeDMEM,andtreatedwith
LPA in DMEM for 1 h. Cycloheximide (10 μg/ml) was included
during DMEM or CM incubation and LPA stimulation. Total
cell lysates were prepared by ﬁrst scraping cells in the presence
of 1 ml homogenization buffer (0.25 M sucrose, 20 M Tris/HCl
pH 7.0, protease and phosphatase inhibitors: 20 μg/ml aprotinin,
5 μg/ml leupeptin, 1 μM pepstatin A, 1 mM PMSF and 2 mM
Na3VO4), and then homogenizing for 1 min with agitation on ice
in a 1.5 ml tube using an electric pestle. The homogenates were
centrifuged at 700 g for 10 min at 4◦C to remove cell debris and
nuclei. The supernatant was subjected to a second centrifugation
at 100000 g for 1 h at 4◦C. The pellet was dissolved in 1×SDS
sample buffer and subjected to Western blot analysis.
Statistics
A Student’s t test was used to assess statistical signiﬁcance.
P<0.05 was considered statistically signiﬁcant.
RESULTS
A bioassay for LPA
Since the activity of LPA can be regulated by a variety of factors
[10,13,19] knowing the concentration of LPA is not sufﬁcient
to accurately predict its bioactivity. Consequently, we sought
to develop an LPA bioassay. To this end, we used a rat hep-
atoma cell line (RH7777), which is unresponsive to LPA [20],
and was modiﬁed to overexpress LPA receptor 1 (L1) or the cor-
responding empty vector (V) [14] (Figure 1A). Phosphorylation
ofpaxillin,oneofthesignallingeventsinducedbyLPA[21],was
markedly better in L1 versus V cells at a number of doses of LPA
(Figure 1B). Further characterization of LPA-triggered phos-
phorylation of paxillin indicated that the response reached a
plateau by 1 h and was linear up to 200 nM LPA (Figure 1C
and results not shown). Although we have not ruled out the pos-
sibility that RH7777 cells express additional LPA receptors, they
did not make a large contribution to phosphorylation of paxillin
(Figure 1B). We conclude that monitoring phosphorylation of
paxillin in this pair of cell lines is one approach to assess the
bioactivity of LPA.
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ECs produced an ILMR (inhibitor of LPA-mediated
responsiveness)
LPA is present in plasma and mediates EC migration and pro-
liferation [1,2,22], yet the endothelium is stable and quiescent
in most vessels of adult animals. While there are many explan-
ations for this apparent paradox, we considered the hypothesis
that vascular ECs in adults are stable and quiescent because they
produce a soluble agent that suppresses their ability to respond to
LPA.TotestthishypothesiswedeterminedifCMfromHUVECs
reducedLPA-mediatedphosphorylationofpaxillin.CMwasgen-
erated by incubating serum-free DMEM with conﬂuent, quies-
cent HUVECs for 18 h. LPA was consistently less potent in the
presence of CM than in the presence of mock CM (DMEM)
(Figure 2A). This reduction in activity was not because the CM
degraded the LPA; the amount of LPA was not decreased by
incubation with CM, rather it tended to increase; however, the
difference did not reach statistical signiﬁcance (Figure 2B). We
conclude that HUVECs produced a soluble inhibitor of LPA-
mediated responsiveness, which we tentatively name ILMR.
CM appeared to inﬂuence the LPA responsiveness
of cells
Possible mechanisms by which ILMR reduced the bioactivity of
LPA involved limiting the ability of LPA to activate its receptor,
or reducing the ability of cells to respond to LPA. Others repor-
ted that, at a sufﬁciently high concentration, the LPA-binding
protein gelsolin inhibits LPA. While CM contained gelsolin,
it was 30-fold below the reported inhibitory concentration [10]
(Figure 3A, left-hand panel). Furthermore, puriﬁed gelsolin, at
theconcentrationpresentinCM,hadnoeffectonLPA’sbioactiv-
ity (Figure 3A, right-hand panel). We conclude that even though
gelsolin was present in CM, its concentration/effect was insufﬁ-
cienttoaccountfortheCM-mediatedattenuationofLPAactivity.
ToinvestigatewhetherCMwasactingoncellsinsteadofLPA,
we altered the experimental protocol to both maximize the ex-
posure of cells to CM and minimize the exposure of LPA to CM.
InsteadoftreatingbothcellsandLPAwithCM,wepre-incubated
cells with CM for 1 h, removed it, rinsed the cells and then stim-
ulated with LPA. Substantially minimizing exposure of LPA to
CM did not prevent the CM from blunting the response to LPA
(Figure 3B). These observations support the idea that CM acted
on cells instead of on LPA. This concept is consistent with our
ﬁnding that diabetes reduced the ability of retinal neovessels to
regress in response to LPA, and that this phenomenon could be
recapitulated by high glucose treatment of primary retinal ECs
[13]. Thus, there is precedent for the idea that the responsive-
ness of cells to LPA is a variable, and subject to environmental
conditions.
In the following series of experiments, we investigated the
mechanism by which CM reduced the responsiveness of cells to
LPA. We considered whether CM reduced expression of LPA1,
and found that this did not appear to be the case. There was no
statisticallysigniﬁcantdeclineinthelevelofLPA1uponexposure
to CM(compare the unstimulated lanes inthe ‘DMEM’ and ‘CM
groups of Figure 4A).
Figure 3 CM appeared to act at the level of cells instead of at
the level of LPA
(A) Left-hand panel panel, CM was subjected to gelsolin Western blot
analysis. The amount of gelsolin in CM was quantiﬁed by comparing
it with a known amount of puriﬁed gelsolin. Right-hand panel, ser-
um-starved L1 cells were either left resting, or stimulated for 1 h with
either 100 nM LPA, 100 ng/ml gelsolin or both. The cells were har-
vested and phosphorylation of paxillin (p-paxillin) was evaluated as de-
scribed in Figure 1. These data show that while gelsolin was present
in CM, the level was insufﬁcient to reduce the bioactivity of LPA. (B)L 1
and V cells were pretreated for 1 h with either DMEM, or CM, rinsed
once with DMEM and stimulated for 1 h with 100 nM LPA. The cells
were harvested and phosphorylation of paxillin was assessed as de-
scribed in Figure 1. *P<0.05. These data show that pre-treating cells
with CM reduced responsiveness to subsequent exposure to LPA, which
suggested that CM acted on cells instead of on LPA.
Next, we tested whether CM altered LPA-induced signalling
events. While LPA promotes internalization of LPA1 [23], and
internalized GPCRs can be either recycled to the cell surface,
or degraded [24], the fate of internalized LPA1 has not been in-
vestigated. We observed that, in LPA-treated cells, the level of
LPA1 in the membrane fraction decreased (Figure 4A), which
suggests that LPA-induced activation of LPA1 promotes its de-
gradation. Importantly, this event was substantially reduced in
CM-treated cells (Figure 4A), suggesting that CM blunted LPA-
inducedsignallingataveryearlystep.Ifthisweretrue,thenphos-
phorylation of paxillin would not be the only signalling pathway
that was compromised. Indeed, LPA-induced phosphorylation of
ERK was also reduced by CM (Figure 4B). As expected from the
work of other investigators [2,25], we found that LPA-dependent
activation of ERK involved signalling intermediates that were
not required for phosphorylation of paxillin (Figure 4C). The
ﬁndings that CM suppressed a spectrum of LPA-dependent sig-
nalling events suggest that ILMR interfered at an early step in
the LPA-triggered signalling cascade.
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Figure 4 CM suppressed the bioactivity of LPA by targeting early LPA-dependent signalling events
Cells were pre-treated with either DMEM or CM as described in Figure 3(B). (A) Pre-treated L1 cells were stimulated
with LPA (100 nM) for 1 h, harvested, the membrane fraction was isolated and subjected to Western blot analysis with
anti-LPA1 and anti-c-Met antibodies. The LPA1 signal intensity was quantiﬁed and normalized to the loading control (c-Met).
A representative blot is shown in the top panel; results from three independent experiments are shown in the bottom panel
as means+ −S.E.M. *P<0.05. n.s.: not signiﬁcant. We conclude that pre-treatment with CM prevented the LPA-induced
reduction in LPA1. (B) Pre-treated L1 cells were stimulated with LPA (100 nM) for 1 h, harvested and subjected to Western
blot analysis using the indicated antibodies. These data showed that CM suppressed the LPA-dependent increase in both
phospho-paxillin (p-paxillin) and phospho-ERK (p-ERK). (C) LPA1 cells were pre-treated as in Figure 3(B), and inhibitors of
LPA1 (5 μM Ki16425; Ki), Src family kinases (5 μM SU6656; SU) or MEK (mitogen-activated protein kinase/ERK kinase)
(5 μM U0126; U) were added during the last 30 min. Cells were subsequently stimulated with LPA (100 nM) for 1 h,
harvested and analysed as in (B). Representative blots are presented; three independent experiments showed similar
results. These ﬁndings conﬁrm the unique requirement of MEK and Src family kinases for LPA-dependent phosphorylation
of ERK and paxillin respectively. (D) Duplicate dishes of pre-treated L1 cells were incubated with LPA-containing medium
for 1 h, the medium was recovered and the amount of LPA was quantiﬁed as in Figure 2(B). The results are presented as a
fraction of the starting amount (medium that was not incubated with cells), which is illustrated in the pair of lanes on the
left. Results from three independent experiments are shown in the bottom panel as means+ −S.E.M. n.s., not signiﬁcant.
In this experiment, the source of LPA was horse serum (0.3%) because puriﬁed LPA was inherently unstable under these
conditions, even in the presence of 0.5% fatty acid-free BSA. The results indicate that cells promoted the degradation of
LPA, and that this parameter was not altered by pre-treatment with CM.
A potential explanation for how CM broadly reduced the
response to LPA is by promoting degradation of LPA. While
Figure 2(B) ruled out the possibility that CM degraded LPA, CM
may increase the expression and/or activity of LPPs. This did not
appear to be the case since the level of all three LPPs remained
unchanged within the 1 h timeframe of a typical experiment (res-
ultsnotshown).Furthermore,whiletherewaslessLPAattheend
of the assay, and this decline was dependent on the presence of
cells (i.e. there was no decrease in the concentration of LPA in
the absence of cells), the magnitude of the decline was compar-
able in both DMEM and CM pre-treated cells (Figure 4D). These
resultsdonotsupporttheideatheCMattenuatedLPA-dependent
responsiveness by accelerating the cell-mediated degradation of
LPA (presumably by LPPs). The data in Figures 3 and 4 indicate
that HUVECs produce and secrete ILMR, and that the mechan-
ism of action seems to be at the level of the cells, perhaps by
compromising LPA-triggered activation of LPA1.
VEGF-A reduced amount and/or activity of ILMR
produced by HUVECs
Since LPA is associated with angiogenesis [26], one may ex-
pect that angiogenic ECs would cease producing ILMR. To
test this idea we investigated whether VEGF-A inﬂuenced the
amount or activity of ILMR produced by HUVECs. As shown in
Figure5(A),CMproducedfromVEGF-Astimulatedcellsfailed
to suppress the bioactivity of LPA. This was not a universal fea-
ture of pro-angiogenic agents; stimulating HUVECs with bFGF
did not inﬂuence production/activity of ILMR. Since VEGF-A
was present in the CM from VEGF-A-stimulated cells, it was
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Figure 5 VEGF, but not bFGF, reduced the amount of LPA inhibitory
activity in CM
(A) The standard protocol to generate CM was modiﬁed such that in-
stead of collecting medium from unstimulated HUVECs, it was harves-
ted from cells that were exposed to 10 ng/ml of either VEGF-A or bFGF
during the 16–18 h interval to generate CM. The resulting panel of
CM, which included DMEM (mock CM) CM (collected from unstimulated
cells) VCM (collected from VEGF-A-stimulated cells) and FCM (collec-
ted from bFGF-stimulated cells), was supplemented with nothing (−)o r
100 nM LPA (+) and added to either V, or L1 cells. After 1 h cells were
harvested, analysed and the resulting data normalized and quantiﬁed
as described in Figure 1. The top panel is a representative blot of L1
cells, while the bottom panel shows results from three independent
experiments; means+ −S.E.M. *P<0.05. The data indicate that VEGF-A
reduced the amount and/or activity of ILMR produced by HUVECs. Con-
trols and experimental samples were run on a single gel and always
analysed in parallel. The lines were added to the Western blotting to in-
dicate where lanes were removed in order to juxtapose the lanes shown
in the Figure. (B) V and L1 cells were left resting or stimulated with either
LPA (100 nM), VEGF-A (10 ng/ml), bFGF (10 ng/ml), LPA+VEGF-A,
or LPA+bFGF for 1 h. Cells were harvested, analysed and the resulting
data normalized and quantiﬁed as described in Figure 1. The top panel
is a representative blot of L1 cells, while the bottom panel shows res-
ults from three independent experiments; means+ −S.E.M. These data
reveal that VEGF-A and bFGF failed to promote phosphorylation of pax-
illin in Rh7777 cells, and did not alter the ability of LPA to trigger this
response. n.s., not signiﬁcant.
possible that VEGF-A promoted phosphorylation of paxillin,
which had an impact upon the interpretation of the effect of
Figure 6 ILMR suppressed LPA-induced migration of HDMVECs
(A) HDMVECs were plated on to the ﬁlter insert of a Boyden chamber and
placed on top of wells containing one of the four types of CM described
in Figure 5 that was (black bars) or was not (white bars) supplemented
with 500 nM LPA. Pilot experiments indicated that this dose of LPA
optimally induced migration (results not shown). The duration of the
assay was 4 h. Means+ −S.E.M. of three independent experiments are
presented in the histogram. *P<0.05; n.s.: not signiﬁcant. The results
indicate that the impact of the panel of CM on LPA-induced migration
of ECs was comparable with its effect on LPA-induced phosphoryla-
tion of paxillin in Rh7777 cells (Figure 4A). (B) HDMVECs were subjected
to a Boyden-chamber-based migration assay in which the bottom wells
contained DMEM alone (0), 100 nM LPA, 10 ng/ml VEGF-A or bFGF.
The assay was ended after 4 h and the data were processed as in (A).
The results indicate that, unlike LPA, VEGF-A and bFGF failed to induce
migration within 4 h. (C) Similar to the experiment shown in (B), except
that the time course was extended to 16–18 h. The results conﬁrm that
VEGF-A and bFGF promoted migration of ECs, and demonstrated that
the time course of this response was slower than when driven with LPA.
*P<0.05 and **P<0.01.
ILMR.However,thisdidnotseemtobethecase;VEGF-Afailed
tostimulatephosphorylationofpaxillin,anddidnotinﬂuencethe
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magnitude of this response in LPA-treated cells (Figure 5B). We
conclude that VEGF-A reduced the amount and/or activity of
ILMR produced by HUVECs.
Finally, we assessed whether ILMR attenuated LPA-mediated
migrationofECs.Tothisend,wemonitoredLPA-inducedmigra-
tionofHDMVECs(Figure6A).CMproducedfromunstimulated
or bFGF-stimulated HUVECs attenuated this response, whereas
CM from VEGF-stimulated cells was ineffective (Figure 6A). In
this set of experiments, we avoided the contribution of VEGF
and bFGF (which were present in the CM collected from VEGF-
A and bFGF-stimulated cells) by monitoring migration before
these growth factors had a detectable inﬂuence. While 4 h was
sufﬁcient to observe LPA-induced migration (Figure 6B), 16–
18 h was required for HDMVECs to respond to VEGF-A and
bFGF. We conclude that ILMR had an impact upon not only
LPA-triggered signalling events in a model cell line (RH7777),
but also attenuated LPA-stimulated cellular responses in at least
one type of EC.
DISCUSSION
In the present paper, we report that VEGF-A suppressed the
amount and/or activity of ILMR, a secreted agent that attenuated
responsiveness of cells to LPA. ILMR appeared to act at the
level of cells, by blocking LPA-dependent signalling events and
cellular responses such as migration.
A shortcoming of our newly developed LPA bioassay is that it
islimitedtoLPA1.Thisraisestheobviousquestionofwhetherthe
effect of ILMR extends to the other ﬁve LPA receptors. The fact
that ECs express multiple LPA receptors [27], and the observa-
tion that ILMR blunted LPA-mediated migration of HDMVECs
(Figure 6), suggests that LPA1 is not the only receptor subject to
the inﬂuence of ILMR.
A question that arises from our observations is the mechanism
of action of ILMR. Since ILMR attenuated multiple, early LPA-
dependent signalling events without inﬂuencing the amount of
LPA, we speculate that ILMR desensitizes LPA1. Supporting
this idea is the observation that GPCR kinase 2, a kinase that
phosphorylates and desensitizes GPCRs [28], also desensitizes
LPA1 [29]. Furthermore, activation of protein kinase C family
members is associated with internalization of LPA1 indepen-
dentlyofagonistoccupation[12].Additionalstudiesarerequired
to elucidate the mechanism of action by which ILMR attenuates
LPA-dependent events and to determine how many of the LPA
receptor family members are subject to this mode of regulation.
An additional burning question is the identity of ILMR. Such
information is likely to advance our understanding of the in-
direct action of VEGF-A and reveal additional regulators of
LPA-mediated events. In light of the breadth of action of LPA,
identiﬁcation of ILMR, an agent that blunts responsiveness to
LPA, is likely to guide development of therapeutic strategies
to combat cancer and other angiogenesis-dependent pathologies.
The canonical view of how VEGF-A promotes angiogenesis
is by engaging its receptors that trigger signalling events leading
to cellular responses required for the angiogenic programme.
Our ﬁnding that VEGF-A reduced antagonism of LPA-mediated
responsessuggeststhatVEGF-Amayalsopromoteangiogenesis
byincreasingresponsivenessofECstoadditionalpro-angiogenic
agents such as LPA.
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